Ionis Pharmaceuticals Company Insiders

Ionis Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.0568) % which means that it has lost $0.0568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4004) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.14 in 2026. Return On Capital Employed is likely to drop to -0.17 in 2026. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 462.9 M in 2026, whereas Net Tangible Assets are likely to drop slightly above 531.9 M in 2026. Common Stock Shares Outstanding is likely to drop to about 86.2 M in 2026. Net Loss is likely to gain to about (230.6 M) in 2026The majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as Ionis Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ionis Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Ionis Pharmaceuticals Workforce Comparison

The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.02.

Ionis Pharmaceuticals Insider Trading History

Ionis Pharmaceuticals Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Ionis Pharmaceuticals often depends on how effective the management is. Ionis Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ionis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ionis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Ionis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ionis Pharmaceuticals. Check Ionis Pharmaceuticals' Beneish M Score to see the likelihood of Ionis Pharmaceuticals' management manipulating its earnings.

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.